Table 5.

Clinical details of the aHUS patients with factor H autoantibodies

Patient ID	Age at presentation, y	Sex	Clinical outcome	Length of follow-up, y	Transplanted	C3, g/L	C4, g/L	Factor H, g/L	Factor I, mg/L
1	5	M	Recovered renal function. 2 relapses. On PE 2×/week	2	No	0.61	0.1	0.37	39
2	11	M	Recovered renal function	5	No	0.57	0.15	0.44	70
3	8	F	ESRF	9	No	0.86	0.25	0.49	58
4	4	F	ESRF	1	No	0.89	0.3	0.52	41
5	10	F	ESRF	5	Yes, 3 y no recurrence	0.92	0.2	0.29	n/a
6	8	M	ESRF	6	No	1.08	0.36	0.5	74
7	6	M	ESRF	7	Yes, 2 years no recurrence	0.77	0.28	0.56	77
8	1	M	Recovered renal function	4	No	1.59	0.38	0.67	75
9	9	F	Recovered renal function	11	No	n/a	n/a	0.63	n/a
10	5	M	Recovered renal function; multiple relapses; PE 1×/2 weeks	3	No	1.06	0.13	0.45	68
11	4	F	Recovered renal function; 3 relapses treated with PE	6	No	0.85	0.24	n/a	n/a
12	10	F	ESRF	8	Yes, 6 y no recurrence	0.51	0.23	0.57	62
13	9	F	Recovered renal function	8	No	n/a	n/a	n/a	n/a

aHUS indicates atypical hemolytic uremic syndrome; ESRF, end-stage renal failure; F, female; M, male; n/a, not available; and PE, plasma exchange.